Active Pharmaceutical Ingredients (APIs) for cancer refer to the key chemical components in medications specifically designed to treat various forms of cancer. These APIs are responsible for the therapeutic effects of cancer drugs. Numerous pharmaceutical companies specialize in the development and manufacturing of APIs for cancer treatment.
Amgen's Acquisition of Rodeo Therapeutics: In March 2021, Amgen, a leading biotech company, acquired Rodeo Therapeutics for $720 million. Rodeo specializes in developing small-molecule cancer treatments, and this acquisition strengthens Amgen's oncology pipeline, particularly in areas like targeted protein degradation.
Teva and MEDinCell's FDA Approval for Schizophrenia Treatment: In August 2021, Teva Pharmaceutical Industries and MEDinCell received FDA approval for Olinvyk Duo, a new long-acting injectable medication for schizophrenia. This approval marks a significant step forward in treating this debilitating mental illness.
Sandoz and Adalvo's Distribution Partnership: In May 2023, Sandoz International, a generic drug giant, entered into a distribution and partnership agreement with Adalvo. This deal grants Adalvo exclusive marketing rights in the US for six Sandoz medicines across various therapeutic areas, including cancer, lung diseases, and antifungals.
Propanc Biopharma's Phase I Trial: In May 2022, Propanc Biopharma, a clinical-stage biopharmaceutical company developing novel cancer treatments, announced the purchase of pharma-grade raw materials for the manufacturing of PRP in preparation for their Phase I First-In-Human (FIH) study. This study will evaluate PRP in patients with advanced solid tumors.
Active Pharmaceutical Ingredient for Cancer Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)